In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma.

In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma.

Publication date: May 09, 2019

Multiepitope cancer vaccines are announcing themselves as the future of melanoma treatment. Herein, high immunogenic regions of transmembrane protein 31 (TMEM31) antigen were selected according to cytotoxic T lymphocytes’ (CTL) epitopes and major histocompatibility complex (MHC) binding affinity through in silico analyses. The 32-62, 77-105, and 125-165 residues of the TMEM31 were selected as the immunodominant fragments. They were linked together by RVRR and HEYGAEALERAG motifs to improve epitopes separation and presentation. In addition, to activate helper T lymphocytes (HTL), Pan HLA DR-binding epitope (PADRE) peptide sequence and tetanus toxin fragment C (TTFrC) were incorporated into the final construct. Also, the Beta-defensin conserved domain was utilized in the final construct as a novel adjuvant for Toll-like receptor 4/myeloid differentiation factor (TLR4-MD) activation. The CTL epitopes, cleavage sites, post-translational modifications, TAP transport efficiency, and B cells epitopes were predicted for the peptide vaccine. The final construct contained multiple CTL and B cell epitopes. In addition, it showed 93.55% and 99.13% population coverage in the world for HLA I and HLA II, respectively. According to these preliminary results, the multiepitope cancer vaccine can be an appropriate choice for further experimental investigations.

Safavi, A., Kefayat, A., Abiri, A., Mahdevar, E., Behnia, A.H., and Ghahremani, F. In silico analysis of transmembrane protein 31 (TMEM31) antigen to design novel multiepitope peptide and DNA cancer vaccines against melanoma. 22597. 2019 Mol Immunol (112):

Concepts Keywords
Adjuvant Chang Yi Wang
Antigen Immunodominance
Binding Affinity Major histocompatibility complex
Cleavage Epitope
Cytotoxic Antigen
Defensin Immunogenicity
DR Branches of biology
Epitope Immune system
Epitopes Immunology
HLA Medicine
Immunogenic Medical specialties
Lymphocytes Melanoma treatment
Major Histocompatibility Complex Future melanoma
Melanoma
MHC
Myeloid
Peptide
Receptor
TLR4
Transmembrane
Vaccine

Semantics

Type Source Name
disease MESH multiple
gene UNIPROT FLNB
gene UNIPROT USO1
gene UNIPROT SEC14L2
gene UNIPROT NXF1
gene UNIPROT SLC35G1
gene UNIPROT TLR4
disease DOID tetanus
disease MESH tetanus
gene UNIPROT ADA2
disease MESH separation
gene UNIPROT HLA-C
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
disease DOID cancer
disease MESH cancer
gene UNIPROT TMEM31

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *